Drug Profile
Research programme: coxsackievirus vaccine - UNEmed
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator UNEmed Corporation
- Developer UNeMed Corporation
- Class Enterovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coxsackievirus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Coxsackievirus-infections in USA
- 03 Apr 2007 This programme is still in active development
- 06 Sep 2002 This programme is still in active development